Paysign (PAYS) shares soared 35.8% in Wednesday trading, significantly outperforming the S&P 500 and Nasdaq, which were up 0.7% and 0.9%, respectively. The surge follows the company’s fourth-quarter earnings report, which revealed sales of $22.76 million—exceeding analyst expectations of $21.55 million. Despite the rally, PAYS is still down about 1% year-to-date, highlighting the volatility surrounding the stock.
The impressive quarterly performance, with nearly 26% year-over-year revenue growth, is bolstered by optimistic forward guidance for 2026. Paysign anticipates sales between $106.5 million and $110.5 million, suggesting a potential annual growth rate of approximately 32.5%. This growth is expected to be driven by strong demand in both its pharmaceuticals and plasma segments, with projected net income rising significantly from $7.55 million to between $13 million and $16 million.
For market professionals, Paysign’s robust earnings outlook and expanding margins could signal a sustained upward trajectory, making it a stock to watch in the healthcare fintech space.
Source: fool.com